文献速递支持与姑息治疗

晚期癌症患者的长期参与:EPAC随机临床试验结果

Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

本研究为EPAC随机临床试验的随访研究,纳入213例晚期癌症患者,评估非专业卫生工作者主导的预立医疗照护计划干预与常规照护相比对总生存及临终医疗使用与费用的关联。干预组死亡风险降低25%(HR 0.75,95%CI 0.56-0.98),安宁疗护与临终关怀使用更多,急诊就诊、住院及总医疗费用更低。

要点

  • 干预组死亡风险降低25%(HR 0.75,95%CI 0.56-0.98)。
  • 干预组安宁疗护使用50.0% vs 对照组35.0%,临终关怀使用72.7% vs 53.0%。
  • 干预组急诊就诊22.7% vs 47.0%,住院19.3% vs 46.0%,总医疗费用中位数更低。

核心结论

  • 非专业卫生工作者主导的干预效果持久,随访近乎完整,支持将其整合入常规癌症照护。

研究设计与样本

  • EPAC随机临床试验的随访研究,2013年8月至2015年2月开展,首例患者入组后随访9.4年,数据截止2023年2月1日。
  • 纳入美国退伍军人事务部帕洛阿尔托医疗系统213例III期、IV期或复发癌症患者,随机接受6个月非专业卫生工作者主导的教育与支持干预或常规照护,采用意向性分析。

主要发现

  • 至2023年2月1日,188例患者死亡;干预组死亡风险降低25%(HR 0.75,95%CI 0.56-0.98)。
  • 干预组安宁疗护使用44例(50.0%)vs 对照组35例(35.0%),临终关怀使用64例(72.7%)vs 53例(53.0%)。
  • 干预组急诊就诊20例(22.7%)vs 47例(47.0%),住院17例(19.3%)vs 46例(46.0%)。
  • 干预组总医疗费用中位数(IQR)为1637美元(383-9026)vs 对照组18520美元(4790-50729)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The long-term effect of interventions that assist patients with establishing their end-of-life care preferences among patients with cancer remain relatively unknown. OBJECTIVE: To evaluate the association of a long-term intervention of a lay health worker-led advance care planning intervention among patients with advanced stages of cancer with overall survival and end-of-life health care use and costs. DESIGN, SETTING, AND PARTICIPANTS: This follow-up study of the EPAC randomized clinical trial conducted between August 2013 and February 2015 used data from 9.4 years after the first patient was enrolled with a data cut-off date of February 1, 2023. Overall, 213 participants with stage 3 or 4 or recurrent cancer in the US Veterans Affairs Palo Alto Health Care System were included. INTERVENTIONS: A 6-month lay health worker-led education and support intervention to assist patients with establishing their end-of-life preferences vs usual care. MAIN OUTCOMES AND MEASURES: The outcomes of interest were overall survival, risk of death, restricted mean survival time, and palliative care, hospice, and acute care use in the final 30 days before death for participants who died. RESULTS: Among 213 participants randomized and included in the intention-to-treat analysis, the mean (SD) age was 69.3 (9.1) years; 211 (99.1%) were male, 2 (0.90%) were female. There were no demographic or clinical characteristic imbalances at enrollment. As of February 1, 2023, 188 had died. The intervention group had a 25% reduction in risk of death (hazard ratio, 0.75; 95% CI, 0.56-0.98); more palliative care (44 [50.0%] vs 35 [35.0%]) and hospice use (64 [72.7%] vs 53 [53.0%]); and lower emergency department use (20 [22.7%] vs 47 [47.0%]), hospitalizations (17 [19.3%] vs 46 [46.0%]), and median (IQR) total health care costs (median [IQR], $1637 [$383-$9026] vs $18 520 [$4790-$50 729]) than control group participants. CONCLUSIONS AND RELEVANCE: The effects of the lay health worker-led intervention remain durable, with nearly complete follow-up, supporting integration into routine cancer care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02966509.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Patel MI, Agrawal M, Blayney DW, et al. Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38814627. doi:10.1001/jamaoncol.2024.1221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。